ANCHENG BIOTECHNOLOGY
Ancheng Biotechnology Co., Ltd. (hereinafter referred to as Ancheng Biotech) is a new drug research and development company headquartered in Taipei, Taiwan, which develops and treats rare diseases. The strategy is to re-position the drug molecules already in clinical use. There is no need for good medicine or emerging medicines, especially for rare diseases that are severely and drug-free. They aim to be efficient and innovative, providing safe and effective new drugs to patients in need around the world.
ANCHENG BIOTECHNOLOGY
Industry:
Biotechnology Pharmaceutical
Address:
Taipei, T'ai-pei, Taiwan
Country:
Taiwan
Website Url:
http://www.twibiotech.com
Status:
Active
Contact:
+886-2-2657-1788
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Google Tag Manager Google Analytics Google Maps LetsEncrypt SSL By Default Font Awesome
Similar Organizations
Alchemedicine
Alchemedicine is a drug research and development company.
Biovalorem
Biovalorem is a biotechnology research and leveraging technology company.
Finoso Pharma
Finoso Pharma is a full-service formulation research and development services company.
Kyoto Pharmaceutical Industries
This company is a focusing on three pillars: new drug research, new drug development and production.
Oneness Biotech
Oneness Biotech is a drug research and development company.
Shanghai Songli Biotechnology
Shanghai Songli Biotechnology is an independent research and development high-tech enterprise.
Official Site Inspections
http://www.twibiotech.com Semrush global rank: 6.1 M Semrush visits lastest month: 1.13 K
- Host name: 125-227-31-219.hinet-ip.hinet.net
- IP address: 125.227.31.219
- Location: Taipei Taiwan
- Latitude: 25.0478
- Longitude: 121.5318
- Timezone: Asia/Taipei
More informations about "Ancheng Biotechnology"
安成生物科技 TWi Biotechnology, Inc.
Oct 28, 2024 安成生物科技股份有限公司(TWi Biotechnology, Inc.)是一家研發治療罕見疾病的新藥研發公司，策略係以重新定位(Drug Reposition)已在臨床使用的藥物分子，滿足目前尚未有良好醫藥或新興醫藥的需求，尤其是以嚴重及無藥 …See details»
安成生物科技 TWi Biotechnology, Inc.
2024-11-27. AC-203 has received approval from the Greece to conduct Phase 2/3 clinical trial. Announcement: The company has developed a new drug, AC-203, for the treatment of …See details»
安成生物科技 TWi Biotechnology, Inc.
安成生物科技股份有限公司(以下簡稱安成生技)是一家總部位於台灣台北市研發治療罕見疾病的新藥研發公司，策略係以重新定位(Drug Reposition)已在臨床使用的藥物分子，滿足目前尚未有 …See details»
Ancheng Biotechnology - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +886-2-2657-1788 Ancheng Biotechnology Co., Ltd. (hereinafter referred to as Ancheng Biotech) is a new drug research and …See details»
TWi Biotechnology Company Profile | Management and …
TWi Biotechnology Profile and History. TWi Biotechnology, Inc. is an clinical development stage company based in Taipei, Taiwan, which specializes in the development of new drugs for rare …See details»
TWi Biotechnology - Overview, News & Similar companies
Jun 2, 2023 TWi Biotechnology Exploring Promising Treatment for Granuloma Annulare (GA) Company and Yale University Hospital seeking participants with GA for Phase 1 trials of …See details»
TWi Biotechnology Company Description - Stock Analysis
1 day ago TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development …See details»
TWi Biotechnology - Craft
Oct 29, 2024 Gross profit (FY, 2023)NT$403.0K Net income (FY, 2023)(NT$170.7M) Cash (FY, 2023)NT$151.8M EBIT (FY, 2023)(NT$169.2M) Enterprise value $1.2BSee details»
TWi Biotechnology, Inc. (安成生物科技股份有限公司) - 药物管线_ …
了解TWi Biotechnology, Inc. (安成生物科技股份有限公司)公司的药物管线，治疗领域，技术平台，以及它的10项临床试验, 8篇新闻和2篇文献，疾病领域:免疫系统疾病，神经系统疾病，血液 …See details»
TWi Biotechnology - VentureRadar
Website: http://www.twibiotech.com/ Develops repositioned drugs for unmet medical needs, focusing on rare diseases associated with innate immunity, including ...See details»
TWi Biotechnology 安成生物科技股份有限公司 | LinkedIn
TWi Biotechnology 安成生物科技股份有限公司 | 139 位 LinkedIn 關注者。Focus on rare diseases development, with an estimated 6 to 8% of the population suffering from rare diseases | TWi …See details»
TWi Biotechnology - PitchBook
TWi Biotechnology General Information Description. TWi Biotechnology Inc is a clinical-stage biopharmaceutical company based in Taiwan. It is engaged in the development of new drugs …See details»
安成生物科技 TWi Biotechnology, Inc.
8F, No.41, Ln. 221, Gangqian Rd., Nei Hu Dist., Taipei 114723, Taiwan. [email protected] +886-2-2657-1788 +886-2-2657-0270See details»
TWi Biotechnology, Inc. (6610.TWO) - Yahoo Finance
TWi Biotechnology, Inc., a clinical-stage biopharmaceutical company, develops and sells drugs for innate immunity-related diseases in Taiwan. The company development pipeline comprises …See details»
6610.TWO - | Stock Price & Latest News | Reuters
Nov 28, 2024 Get Twi Biotechnology Inc (6610.TWO) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsSee details»
TWi Biotechnology Exploring Promising Treatment for Granuloma …
Jun 2, 2023 Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments. NEW HAVEN, Conn., June 2, 2023 …See details»
TWi Biotechnology Exploring Promising Treatment for ... - BioSpace
Jun 2, 2023 Company and Yale University Hospital seeking participants with GA for Phase 1 trials of medicine FDA-approved for other ailments. NEW HAVEN, Conn., June 2, 2023 …See details»
TWi Biotechnology Announces Last Patient Enrolled in Phase 2 …
TAIPEI, Taiwan, Jan. 22, 2019 /PRNewswire/ -- TWi Biotechnology Inc. (TWiB), a clinical stage biopharmaceutical company focused on development of novel products for rare diseases …See details»
安成生物科技 TWi Biotechnology, Inc.
Feb 7, 2018 “Because although most of EB patients are type Simplex (70%), and type Dystrophic (25%) and type Juncture (5%) are the minority among EB patients, their symptoms …See details»
TWi Biotechnology Receives Canada Health Approval for AC-1101 …
TAIPEI, Taiwan, May 7, 2020 /PRNewswire/ -- TWi Biotechnology (TWiB) announced that they have received Clinical Trial Application (CTA) approval from the Health Canada to conduct a …See details»